Research and Markets: In 2008, the Export Amounts of Chinese Raw Material Medicines Totalled 18 Billion USD Says the 2009 Research Report on Chinese Chemical Pharmaceuticals Industry

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/cdf061/research_report_on) has
announced the addition of the "Research Report on Chinese Chemical
Pharmaceuticals Industry, 2009" report to their offering.

The chemical pharmaceuticals industry is the largest sub-sector of Chinese
pharmaceuticals industry. In 2008, the sales revenues of Chinese chemical raw
material medicines were 26.5 billion USD and the sales revenues of the chemical
preparation industry were 3.34 billion USD, with the average growth rate all
exceeding 20%. In 2008, China produced 2.2853 million tons chemical raw material
medicines accumulatively, YOY up by 0.85% with the growth rate down by 15.05%
compared with the same period of last year.

Because of the rigid demands for the pharmaceuticals, the influences of the
international financial crisis on the pharmaceuticals industry were limited. In
2008, the export amounts of Chinese raw material medicines totalled 18 billion
USD. From the aspect of the export volumes of the raw material medicines, the
previous leading mass raw material medicines have been the major export variety
in the international market so far. Because of the price advantage of the raw
material medicines in the international market, it is predicted that the exports
of Chinese raw material medicines will hold the line in 2009 to 2010.

In 2008, the export volumes of the Penicillin-G totaled 12 thousand tons,
holding the line compared with 2007, but the average export price was increased.
In 2009, with the influences of the grain price growth, the production costs
were increased. Therefore, the major international manufacturers of
semi-compound Penicillin-G will probably accelerate the import volumes of
Chinese Penicillin-G.

According to the statistics, the accumulative export volumes of various
tetracycline raw material medicines were 14 thousand tons in 2008 in China,
exceeding the Penicillin-G in volume and standing the largest export raw
material medicine variety in China. With the gradual discovery of the new uses
of the tetracycline and the derivatives in the international pharmaceuticals
field, the tetracycline antibiotics will not come to an end with the spring-up
of the cefa-antibiotics just like what people predict. Conversely, the
tetracycline and the derivatives will take certain place tightly in the
international pharmaceuticals market (the tetracycline antibiotics are also can
be used as the additives of the animal feed stuffs, there is large demands in
the international market). It is predicted that the tetracycline will be one of
the major export raw material medicine varieties in the next several years, with
the export volumes exceeding ten thousand tons.

Cephalosporin is the leading antibiotics in the international pharmaceuticals
market. At present, the best-sellers conclude 20 varieties, 80% of which can be
produced in China. In 2008, China totally exported about 500 tons, in which
ceftriaxone sodium accounted for 40%. A new export characteristic of Chinese
cephalosporin is the export growth of the cefaclor. From the part of the cost
performance ratio, cefaclor is the commendable common antibiotics in the
clinical experiments, meanwhile, the domestic producing technologies have been
mature and many technology indicators have few differences with the
international advanced level. In consideration of the work force and cost
advantages, many overseas manufacturers set up the cephalosporin production
bases in China and produced the export cephalosporin raw material products.

China is the biggest producing and exporting country of the antipyretic
analgesic products, the three largest export products including aspirin,
paracetamol and Ibuprofen as well as Naproxen Sodium, Diclofenic Sodium and
Analgin DAB. The respective export volumes of paracetamol, aspirin and Ibuprofen
were 48.9 thousand tons, 30 thousand tons and 10 thousand tons in 2008. Because
of the low prices, many countries including Europe and India put forward
anti-dumping accusation of Chinese mass export antipyretic analgesic products,
making Chinese export enterprises in the passive position.

The hot vitamin varieties in the international market were as follows: first,
the natural vitamin E which was extracted from the vegetable oil trash, the
demands exceeding the supplies for a long time in the international market. It
was understood that the export volumes of the natural vitamin E in Zhejiang had
been to 5 hundred tons with the export price 60% higher than the compound VE;
second, the vitamin H which had been discovered with the new use of health care,
for example, it could be processed into hypoglycemic compound agent together
with chromium preparation. Therefore, the export would be increased. The export
volumes of Chinese vitamin H accounted for 45% in the international market.

The export medicines against the cardiovascular disease can be divided into two
parts: one is the depressor and the other is anti-lipemic agents. The statistics
showed that the growth rate of the depressor and anti-lipemic agents was
increased greatly, especially the best-sellers of statins, prils and sartans,
which had been the major export raw material medicines against the
cardiovascular disease in the international market.

In 2008, the export volumes of the statins totaled 500 tons. China had been
capable of producing 8 to 9 varieties of the statin raw material medicines. Some
multinational pharmaceuticals enterprises intended to produce the statin raw
material medicines in China and then the products exported to European and
American for the preparation production.

More following information can be obtained in this report:

* Present Development Situation of Chinese Chemical Pharmaceuticals Industry
* Policy Environments for the Development of Chinese Chemical Pharmaceuticals
Industry
* Imports and Exports of Chinese Chemical Pharmaceuticals Industry
* Major Enterprises and Their Operations of Chinese Chemical Pharmaceuticals
Industry
* Factors affecting the Development of Chinese Chemical Raw Material Medicine
Industry
* Influences of International Financial Crisis on Chinese Chemical
Pharmaceuticals Industry
* Investment Opportunities of Chinese Chemical Pharmaceuticals Industry
* Development Trends of Chinese Chemical Pharmaceuticals Industry

For more information visit
http://www.researchandmarkets.com/research/cdf061/research_report_on

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009